Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06713239 · ClinicalTrials.gov registry record · NA

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

A NA study of Coronary Artery Disease, sponsored by Cleerly.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
20
Study locations

NCT06713239 is a NA study of Coronary Artery Disease that is actively recruiting participants, run by Cleerly. The registered enrollment target is 1,000 participants, below the 1,282-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06713239, a NA study of Coronary Artery Disease, is actively recruiting participants, sponsored by Cleerly.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptomatic patients with suspicion of CAD.

Conditions Studied

Coronary Artery Disease

Interventions

  • DEVICE Cleerly Labs and Cleerly ISCHEMIA

Study Locations (20)

California

  • Valiance Clinical Research- Huntington Park - Huntington Park
  • Cardiovascular Institute of San Diego - San Diego
  • Valiance Clinical Research- Tarzana - Tarzana
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance

Florida

  • Tampa Cardiovascular Interventions and Research - Tampa
  • Flourish Research - Winter Park

Alabama

  • Cardiology Associates of Mobile - Mobile

Colorado

  • Intermountain Health Saint Joseph Hospital - Broomfield

Illinois

  • Endeavor Health Clinical Operations - Evanston

Iowa

  • MercyOne Des Moines Medical Center - West Des Moines

Kentucky

  • Saint Elizabeth Medical Center - Edgewood

Louisiana

  • Tulane University - New Orleans

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-12-18
Est. Completion 2026-10
Phase NA

Sponsor

Cleerly

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06713239

The ClinicalTrials.gov registry entry for NCT06713239 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,282-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (22% lower). The listed sponsor is Cleerly, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Cleerly Labs and Cleerly ISCHEMIA is the first listed.

NCT06713239 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT06713239 about?

NCT06713239 is a clinical study titled "A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD". PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: cer...

What is the current status of trial NCT06713239?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-12-18. Estimated completion is 2026-10.

What conditions does trial NCT06713239 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT06713239?

The interventions under investigation include: Cleerly Labs and Cleerly ISCHEMIA (DEVICE).

Who is sponsoring clinical trial NCT06713239?

This trial is sponsored by Cleerly, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06713239 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.